Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors

Sponsor
NYU Langone Health (Other)
Overall Status
Completed
CT.gov ID
NCT02011685
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (NIH)
450
1
2
68.4
6.6

Study Details

Study Description

Brief Summary

This study will assess the comparative effectiveness, cost-effectiveness and sustainability of two telemonitoring interventions in reducing blood pressure and recurrent stroke among 450 high-risk Black and Hispanic stroke patients. The primary hypothesis is that home blood pressure telemonitoring supplemented with individualized, culturally tailored telephone-based nurse case management will have greater effects on blood pressure reduction and stroke recurrence and, while it will be more costly, it will also be more cost-effective than home blood pressure telemonitoring alone. Results of this study will provide strong empirical evidence to inform clinical guidelines and practice, which may lead to reductions in stroke disparities in the United States.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Home BP Telemonitoring (HBPTM)
  • Behavioral: Nurse Case Management (NCM)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
450 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors
Actual Study Start Date :
Apr 18, 2014
Actual Primary Completion Date :
Nov 30, 2019
Actual Study Completion Date :
Dec 31, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Home BP Telemonitoring (HBPTM)

Participants will take home BP readings 3 days per week (morning and evening) for one week out of each month during the 12-month intervention.

Behavioral: Home BP Telemonitoring (HBPTM)
Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.

Experimental: HBPTM + Nurse Case Management (NCM)

Participants will complete the same Home BP Telemonitoring protocol and will also complete 20 counseling phone calls with a nurse case manager during the 12-month intervention.

Behavioral: Home BP Telemonitoring (HBPTM)
Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.

Behavioral: Nurse Case Management (NCM)
Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12. The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication. They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques. Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).

Outcome Measures

Primary Outcome Measures

  1. 12-month systolic blood pressure (SBP) change [Baseline, 12 months]

Secondary Outcome Measures

  1. 24-month stroke recurrence [24 months]

  2. Cost-effectiveness for reducing SBP at 12 months [12 months]

  3. Cost-effectiveness for reducing stroke recurrence at 24 months [24 Months]

Other Outcome Measures

  1. Change in other stroke risk factors [6, 12, 24 months]

    lipids, blood glucose

  2. Change in health behaviors [6, 12, 24 months]

    diet, physical activity, medication adherence, weight loss

  3. Antihypertensive medication intensification [6, 12, 24 months]

    adding, changing dose, or changing class of medications

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Black or Hispanic

  • Age 18 years or older

  • English or Spanish speaking

  • Patients who have had an ischemic or hemorrhagic stroke

  • Modified Rankin scale score of ≤ 3

  • Average screening SBP ≥ 140 mm Hg from three BP readings taken at two separate visits with a validated automated device

  • Receiving care at the study site for at least 6 months and planning to continue receiving care at the site for the next two years.

Exclusion Criteria:
  • Being deemed unable to comply with the study protocol (either self-selected or by indicating during screening that he/she could not complete all requested tasks including using the HBPTM or interacting with the NCM if he/she were to be randomized to the intervention group)

  • Participation in other clinical trials

  • Diagnosis of cognitive dysfunction or significant psychiatric comorbidity (as indicated in medical record)

  • Patients with upper arm circumference ≥ 52 cm, the maximum limit of the extra-large BP cuff

  • Diagnosis of dialysis or end stage renal disease

  • Relocating out of area or extended travel during study period

  • Significant verbal speech impairment; unable to participate in intervention telephone sessions

  • Pregnant women

Contacts and Locations

Locations

Site City State Country Postal Code
1 NYU School of Medicine New York New York United States 10016

Sponsors and Collaborators

  • NYU Langone Health
  • National Institute of Neurological Disorders and Stroke (NINDS)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
NYU Langone Health
ClinicalTrials.gov Identifier:
NCT02011685
Other Study ID Numbers:
  • 13-00281
  • U54NS081765-5162
  • U54NS081765
First Posted:
Dec 13, 2013
Last Update Posted:
Feb 18, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 18, 2022